Progression from human papillomavirus (HPV) infection to cervical lesion or clearance in women (18–25 years): Natural history study in the control arm subjects of AS04-HPV-16/18 vaccine efficacy study in China between 2008 and 2016

References

• Bruni L, Albero G, Serrano B, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report 17 June 2019. [cited 2020 Aug 17].
   Google Scholar
• de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–1056.
   PubMed Web of Science ®Google Scholar
• Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(2):123–137.
   PubMed Web of Science ®Google Scholar
• Chen W, Molijn A, Enqi W, et al. The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: a hospital based nation-wide multi-center retrospective study across China. Int J Cancer. 2016;139(12):2687–2697.
   PubMed Web of Science ®Google Scholar
• Bruni L, Albero G, Serrano B, et al. Human Papillomavirus and Related Diseases in China. Summary Report 17 June 2019. [cited 17 Aug 2020]. Available from: https://hpvcentre.net/statistics/reports/CHN.pdf
   Google Scholar
• de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstetrics Gynaecol. 2018;47:2–13.
   PubMed Web of Science ®Google Scholar
• Appleby P, Beral V, Berrington de Gonzalez A, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118(6):1481–1495.
   PubMed Web of Science ®Google Scholar
• Smith JS, Munoz N, Herrero R, et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis. 2002;185(3):324–331.
   PubMed Web of Science ®Google Scholar
• Jaisamrarn U, Castellsague X, Garland SM, et al. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PloS One. 2013;8(11):e79260.
   PubMed Web of Science ®Google Scholar
• Skinner SR, Wheeler CM, Romanowski B, et al. Progression of HPV infection to detectable cervical lesions or clearance in adult women: analysis of the control arm of the VIVIANE study. Int J Cancer. 2016;138(10):2428–2438.
   PubMed Web of Science ®Google Scholar
• Wentzensen N, Schiffman M, Dunn ST, et al. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int J Cancer. 2009;124(4):964–969.
   PubMed Web of Science ®Google Scholar
• International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120(4):885–891.
   PubMed Web of Science ®Google Scholar
• International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1060–1069.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Chen W, Hu YM, et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial. Int J Cancer. 2014;135(11):2612–2622.
   PubMed Web of Science ®Google Scholar
• Zhu F, Li J, Hu Y, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Hum Vaccin Immunother. 2014;10(7):1795–1806.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Hu SY, Hong Y, et al. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: end-of-study results from a phase II/III, randomised, controlled trial. Cancer Med. 2019;8(14):6195–6211.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–314.
   PubMed Web of Science ®Google Scholar
• Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42(1):121–130.
   PubMed Web of Science ®Google Scholar
• Lin D, Wei L. The robust inference for the Cox proportional hazards model. J Amer Statist Assoc. 1989;84:1074–1078.
   Web of Science ®Google Scholar
• Zhang SK, Kang LN, Chang IJ, et al. The natural history of cervical cancer in Chinese women: results from an 11-year follow-up study in China using a multistate model. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1298–1305.
   PubMed Web of Science ®Google Scholar
• Donken R, Hoes J, Knol MJ, et al. Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches. BMC Infect Dis. 2020;20(1):482.
   PubMed Web of Science ®Google Scholar
• Spruance SL, Reid JE, Grace M, et al. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004;48(8):2787–2792.
   PubMed Web of Science ®Google Scholar